Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29048263 | 1.00 | CHRNB2 (0.32) | CHRNB2CHRNA4CHRNA7 | |
| Hydrochloric Acid SCHEMBL29048250 | 0.98 | CHRNB2 (0.32) | CHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL29048286 | 0.98 | CHRNB2 (0.32) | CHRNB2CHRNA4 | |
| Trifluoroacetic Acid SCHEMBL30338646 | 0.84 | CHRNB2 (0.33) | CHRNB2CHRNA4 | |
| Trifluoroacetic Acid SCHEMBL30339079 | 0.83 | CHRNB2 (0.33) | CHRNB2CHRNA4 | |
| Trifluoroacetic Acid SCHEMBL30338672 | 0.83 | CHRNB2 (0.33) | CHRNB2CHRNA4 | |
| Trifluoroacetic Acid SCHEMBL30581170 | 0.83 | CHRNB2 (0.33) | CHRNB2CHRNA4 | |
| SCHEMBL22689683 | 0.79 | CHRNB2 (0.58) | CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL31200251 | 0.78 | CYP2A6 (0.43) | CHRNB2CHRNA4 | |
| SCHEMBL25816728 | 0.78 | CYP2A6 (0.43) | CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116547281-A | Isoxazolidines as RIPK1 inhibitors and uses thereof | 赛诺菲 | 2023-08-04 | — | — | CN | disclosed |
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | SANOFI (FR) | 2023-07-13 | — | — | US | disclosed |
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | SANOFI (FR) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | RIPK1, RIPK4, RIPK2 | CHRNB2 4268/4885CHRNA4 3645/4885CHRNA7 3172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.